iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy

Nature Cell Biology

Volumn 18, Issue 10, 2016, Pages 1031-1042

  Kodo, Kazuki ^a   Ong, Sang Ging ^a   Jahanbani, Fereshteh ^a   Termglinchan, Vittavat ^a   Hirono, Keiichi ^b   Inanloorahatloo, Kolsoum ^a   Ebert, Antje D ^a   Shukla, Praveen ^a   Abilez, Oscar J ^a   Churko, Jared M ^a   Karakikes, Ioannis ^a   Jung, Gwanghyun ^a   Ichida, Fukiko ^b   Wu, Sean M ^a   Snyder, Michael P ^a   Bernstein, Daniel ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PRDM16; TRANSCRIPTION FACTOR TBX20; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; T BOX TRANSCRIPTION FACTOR; TBX20 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE CELL; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VENTRICULAR NONCOMPACTION; CARDIOMYOPATHY; CONGENITAL HEART MALFORMATION; GENETICS; HEART VENTRICLE; METABOLISM; MUTATION;

CARDIOMYOPATHIES; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTATION; MYOCYTES, CARDIAC; PHENOTYPE; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84988369683     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3411     Document Type: Article

References (55)

1. Kohli, S. K., et al. Diagnosis of left-ventricular non-compaction in patients with leftventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?. Eur. Heart J. 29, 89-95 (2008
2. Nugent, A. W., et al. The epidemiology of childhood cardiomyopathy in Australia. N. Engl. J. Med. 348, 1639-1646 (2003
3. Sedmera, D., Pexieder, T., Vuillemin, M., Thompson, R. P., & Anderson, R. H. Developmental patterning of the myocardium. Anat. Rec. 258, 319-337 (2000
4. Chin, T. K., Perloff, J. K., Williams, R. G., Jue, K., & Mohrmann, R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82, 507-513 (1990
5. Kosaka, Y., et al. 14-3-3epsilon plays a role in cardiac ventricular compaction by regulating the cardiomyocyte cell cycle. Mol. Cell. Biol. 32, 5089-5102 (2012
6. Chen, Q., et al. Smad7 is required for the development and function of the heart. J. Biol. Chem. 284, 292-300 (2009
7. DiMichele, L. A., et al. Transient expression of FRNK reveals stage-specific requirement for focal adhesion kinase activity in cardiac growth. Circ. Res. 104, 1201-1208 (2009
8. Bartram, U., et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-2-knockout mice. Circulation 103, 2745-2752 (2001
9. Shou, W., et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391, 489-492 (1998
10. Grego-Bessa, J., et al. Notch signaling is essential for ventricular chamber development. Dev. Cell 12, 415-429 (2007
11. Luxan, G., et al. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat. Med. 19, 193-201 (2013
12. Arndt, A. K., et al. Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am. J. Hum. Genet. 93, 67-77 (2013
13. Chakraborty, S., & Yutzey, K. E. Tbx20 regulation of cardiac cell proliferation and lineage specialization during embryonic and fetal development in vivo. Dev. Biol. 363, 234-246 (2012
14. Takeuchi, J. K., et al. Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development. Development 132, 2463-2474 (2005
15. Hammer, S., et al. Characterization of TBX20 in human hearts and its regulation by TFAP2. J. Cell. Biochem. 104, 1022-1033 (2008
16. Posch, M. G., et al. A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J. Med. Genet. 47, 230-235 (2010
17. Liu, C., et al. T-box transcription factor TBX20 mutations in Chinese patients with congenital heart disease. Eur. J. Med. Genet. 51, 580-587 (2008
18. Qian, L., et al. Transcription factor neuromancer/TBX20 is required for cardiac function in Drosophila with implications for human heart disease. Proc. Natl Acad. Sci. USA 105, 19833-19838 (2008
19. Kirk, E. P., et al. Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am. J. Hum. Genet. 81, 280-291 (2007
20. Chen, G., et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8, 424-429 (2011
21. Churko, J. M., Burridge, P. W., & Wu, J. C. Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions. Methods Mol. Biol. 1036, 81-88 (2013
22. Burridge, P. W., et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855-860 (2014
23. Wu, H., et al. Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised-Adrenergic signaling in an iPSC model of dilated cardiomyopathy. Cell Stem Cell 17, 89-100 (2015
24. D'Amato, G., et al. Sequential Notch activation regulates ventricular chamber development. Nat. Cell Biol. 18, 7-20 (2016
25. Engelmann, G. L., Boehm, K. D., Birchenall-Roberts, M. C., & Ruscetti, F. W. Transforming growth factor- 1 in heart development. Mech. Dev. 38, 85-97 (1992
26. Kitamura, R., et al. Stage-specific role of endogenous Smad2 activation in cardiomyogenesis of embryonic stem cells. Circ. Res. 101, 78-87 (2007
27. Hauck, L., et al. Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circ. Res. 100, 50-60 (2007
28. Akli, S., Zhan, S., Abdellatif, M., & Schneider, M. D. E1A can provoke G1 exit that is refractory to p21 and independent of activating Cdk2. Circ. Res. 85, 319-328 (1999
29. Brooks, G., Poolman, R. A., & Li, J. M. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc. Res. 39, 301-311 (1998
30. Madisen, L., et al. A robust and high-Throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133-140 (2010
31. Sakabe, N. J., et al. Dual transcriptional activator and repressor roles of TBX20 regulate adult cardiac structure and function. Hum. Mol. Genet. 21, 2194-2204 (2012
32. Sun, N., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147 (2012
33. Davis, J., et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy. Cell 165, 1147-1159 (2016
34. Lan, F., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101-113 (2013
35. Hinson, J. T., et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349, 982-986 (2015
36. Itzhaki, I., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225-229 (2011
37. Wang, Y., et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J. Am. Coll. Cardiol. 64, 451-459 (2014
38. Burridge, P. W., et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547-556 (2016
39. Matsa, E., Ahrens, J. H., & Wu, J. C. Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine. Physiol. Rev. 96, 1093-1126 (2016
40. Takahata, M., et al. SKI and MEL1 cooperate to inhibit transforming growth factor- signal in gastric cancer cells. J. Biol. Chem. 284, 3334-3344 (2009
41. Warner, D. R., et al. PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochim. Biophys. Acta 1773, 814-820 (2007
42. Bjork, B. C., Turbe-Doan, A., Prysak, M., Herron, B. J., & Beier, D. R. Prdm16 is required for normal palatogenesis in mice. Hum. Mol. Genet. 19, 774-789 (2010
43. Oechslin, E., & Jenni, R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity?. Eur. Heart J. 32, 1446-1456 (2011
44. Sen-Chowdhry, S., & McKenna, W. J. Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon?. Curr. Opin. Cardiol. 23, 171-175 (2008
45. Kodo, K., et al. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc. Natl Acad. Sci. USA 106, 13933-13938 (2009
46. Stevenson, K. R., Coolon, J. D., & Wittkopp, P. J. Sources of bias in measures of allelespecific expression derived from RNA-sequence data aligned to a single reference genome. BMC Genomics 14, 536 (2013
47. Abel, E. D., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 104, 1703-1714 (1999
48. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. A global doublefluorescent Cre reporter mouse. Genesis 45, 593-605 (2007
49. Chen, W. P., Liu, Y. H., Ho, Y. J., & Wu, S. M. Pharmacological inhibition of TGF- receptor improves Nkx2.5 cardiomyoblast-mediated regeneration. Cardiovasc. Res. 105, 44-54 (2015
50. Hall, B. E., et al. Conditional overexpression of TGF-1 disrupts mouse salivary gland development and function. Lab. Invest. 90, 543-555 (2010
51. Chang, B., et al. 14-3-3- gene variants in a Japanese patient with left ventricular noncompaction and hypoplasia of the corpus callosum. Gene 515, 173-180 (2013
52. Markell, L. M., Masiuk, K. E., Blazanin, N., & Glick, A. B. Pharmacologic inhibition of ALK5 causes selective induction of terminal differentiation in mouse keratinocytes expressing oncogenic HRAS. Mol. Cancer Res. 9, 746-756 (2011
53. Ran, F. A., et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013
54. Ding, Q., et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238-251 (2013
55. Yusa, K. Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon. Nat. Protoc. 8, 2061-2078 (2013